Advertisement


Aadel A. Chaudhuri, MD, PhD, on Personalizing Treatment for Oligometastatic Cancer

2021 ASTRO Annual Meeting

Advertisement

Aadel A. Chaudhuri, MD, PhD, of Washington University School of Medicine in St. Louis, discusses circulating tumor DNA, which has the potential to better personalize treatment for patients with oligometastatic cancer and help clinicians determine whether to offer systemic therapy alone or curative-intent local consolidative therapy.



Related Videos

Head and Neck Cancer

Daniel J. Ma, MD, on HPV-Associated Oropharyngeal Squamous Cell Carcinoma: Comparing Longer and Shorter Courses of Radiotherapy

Daniel J. Ma, MD, of the Mayo Clinic Alix School of Medicine, discusses results from a phase III study of patients with HPV-associated oropharyngeal squamous cell carcinoma. Comparing a 2-week course of de-escalated adjuvant radiation therapy with the standard 6-week course, investigators found that the shorter treatment appeared to have less toxicity, higher quality of life, and similar disease control as the longer standard-of-care treatment (Abstract LBA1).

Issues in Oncology

Daniel F. Hayes, MD, on Liquid Biopsies to Detect and Monitor Oligometastases

Daniel F. Hayes, MD, of the University of Michigan Rogel Cancer Center, discusses whether liquid biopsies can provide insight into the challenge of curing metastatic breast and possibly other cancers, how oligometastases are similar to a primary cancer, and why some kinds of local therapy for widespread disease might improve survival and lead to a cure.

Solid Tumors

Robert A. Olson, MD, on Oligometastases: New Data on Stereotactic Ablative Radiotherapy

Robert A. Olson, MD, of the University of British Columbia, discusses phase II findings from the SABR-5 trial on stereotactic ablative radiotherapy for up to five oligometastases. Although toxicity of liver and adrenal metastases warrants caution, the trial seemed to show that this type of radiation treatment is relatively safe and should be studied further, given the long overall survival in this patient population (Abstract 6).

Breast Cancer
Lung Cancer

C. Jillian Tsai, MD, PhD, on Using Radiotherapy to Thwart Tumor Growth in Advanced Cancers

C. Jillian Tsai, MD, PhD, of Memorial Sloan Kettering Cancer Center, discusses results from the first randomized trial of stereotactic body radiation therapy (SBRT) to treat oligoprogressive, metastatic lung and breast cancers. The standard of care for patients with these types of tumors is to switch to a different systemic treatment. Adding local therapy such as SBRT may help treat drug-resistant lesions (Abstract LBA3).

 

Head and Neck Cancer

David A. Palma, MD, PhD, on HPV-Associated Oropharyngeal Squamous Cell Carcinoma: Radiotherapy vs Surgery

David A. Palma, MD, PhD, of Ontario’s London Health Sciences Centre, discusses results of the ORATOR2 study, which compared two treatment options that could be de-escalated for patients with HPV-associated oropharyngeal squamous cell carcinoma: a lower-dose radiation approach (6 weeks instead of 7, often with chemotherapy) vs a transoral surgical approach (with low-dose radiation afterward, for 5 weeks) (Abstract LBA2).

Advertisement

Advertisement




Advertisement